Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.
Synergy CHC Corp. (NASDAQ: SNYR) Expands FOCUSfactor® Beverage Platform Further Building Shareholder Value – IMG, YCBD, SURG, URG InsideSynergy CHC Corp. (
NASDAQ: SNYR) continues to build momentum behind its functional beverage strategy, announcing new Direct Store Delivery (DSD) partnerships across Maine and Pennsylvania that expand retail distribution of FOCUSfactor® Focus + Energy RTD beverages and brain-health shots .
MILESTONE ALERT: Bragar Eagel & Squire, P.C. is Investigating Milestone Pharmaceuticals Inc. on Behalf of Milestone Stockholders and Encourages Investors to Contact the FirmNEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Milestone Pharmaceuticals Inc. (“Milestone” or the “Company”) (
NASDAQ: MIST) on behalf of Milestone stockholders. Our investigation concerns whether Milestone has violated the federal securities laws and/or engaged in other unlawful business practices.
ROSEN, A LEADING LAW FIRM, Encourages Milestone Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation – MIST
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Milestone Pharmaceuticals Inc. (
NASDAQ: MIST) resulting from allegations that Milestone may have issued materially misleading business information to the investing public.
